Literature DB >> 15198510

Pharmacokinetic model of target-mediated disposition of thrombopoietin.

Feng Jin1, Wojciech Krzyzanski.   

Abstract

Thrombopoietin, TPO, a 353 amino acid cytokine, is a primary regulator of platelet production that was cloned recently. A target-mediated (platelet receptors) pharmacokinetic model was developed to characterize the disposition of TPO. Receptor-mediated endocytosis was assigned as the major elimination pathway in the model. A nonspecific binding compartment was also incorporated into the model. TPO concentration vs time profiles from a published phase 1 and 2 clinical trial were used to apply this model. Noncompartmental analysis demonstrated that TPO exhibits nonlinear kinetics. The proposed model captured the concentration-time profiles relatively well. The first-order internalization rate constant was estimated as 0.1 h(-1). The endogenous binding capacity was estimated as 164.0 pM. The second-order binding association constant (k(on)) was 0.055 h(-1).pM(-1) and the first-order dissociation constant (k(off)) was estimated as 2.5 h(-1), rendering the equilibrium dissociation constant K(d) as 45.5 pM. This model may be relevant to other therapeutic agents with receptor-mediated endocytotic disposition.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15198510      PMCID: PMC2750944          DOI: 10.1208/ps060109

Source DB:  PubMed          Journal:  AAPS PharmSci        ISSN: 1522-1059


  32 in total

1.  General pharmacokinetic model for drugs exhibiting target-mediated drug disposition.

Authors:  D E Mager; W J Jusko
Journal:  J Pharmacokinet Pharmacodyn       Date:  2001-12       Impact factor: 2.745

Review 2.  Pharmacokinetics of capacity-limited systems.

Authors:  W J Jusko
Journal:  J Clin Pharmacol       Date:  1989-06       Impact factor: 3.126

3.  The effect of thrombopoietin on the proliferation and differentiation of murine hematopoietic stem cells.

Authors:  E Sitnicka; N Lin; G V Priestley; N Fox; V C Broudy; N S Wolf; K Kaushansky
Journal:  Blood       Date:  1996-06-15       Impact factor: 22.113

4.  The Mpl receptor is expressed in the megakaryocytic lineage from late progenitors to platelets.

Authors:  N Debili; F Wendling; D Cosman; M Titeux; C Florindo; I Dusanter-Fourt; K Schooley; N Methia; M Charon; R Nador
Journal:  Blood       Date:  1995-01-15       Impact factor: 22.113

5.  Mean residence time concepts for pharmacokinetic systems with nonlinear drug elimination described by the Michaelis-Menten equation.

Authors:  H Y Cheng; W J Jusko
Journal:  Pharm Res       Date:  1988-03       Impact factor: 4.200

Review 6.  Dose-dependent pharmacokinetics: experimental observations and theoretical considerations.

Authors:  J H Lin
Journal:  Biopharm Drug Dispos       Date:  1994-01       Impact factor: 1.627

Review 7.  Pharmacologic target-mediated drug disposition.

Authors:  G Levy
Journal:  Clin Pharmacol Ther       Date:  1994-09       Impact factor: 6.875

8.  Alterations of routine blood tests in adult patients with soft tissue sarcomas: relationships to cytokine serum levels and prognostic significance.

Authors:  W Ruka; P Rutkowski; J Kaminska; A Rysinska; J Steffen
Journal:  Ann Oncol       Date:  2001-10       Impact factor: 32.976

9.  Molecular cloning and chromosomal localization of the human thrombopoietin gene.

Authors:  Y Sohma; H Akahori; N Seki; T Hori; K Ogami; T Kato; Y Shimada; K Kawamura; H Miyazaki
Journal:  FEBS Lett       Date:  1994-10-10       Impact factor: 4.124

10.  Thrombopoietin, the Mp1 ligand, is essential for full megakaryocyte development.

Authors:  K Kaushansky; V C Broudy; N Lin; M J Jorgensen; J McCarty; N Fox; D Zucker-Franklin; C Lofton-Day
Journal:  Proc Natl Acad Sci U S A       Date:  1995-04-11       Impact factor: 11.205

View more
  14 in total

1.  Theoretical considerations of target-mediated drug disposition models: simplifications and approximations.

Authors:  Peiming Ma
Journal:  Pharm Res       Date:  2011-12-01       Impact factor: 4.200

2.  Pharmacodynamics-mediated drug disposition (PDMDD) and precursor pool lifespan model for single dose of romiplostim in healthy subjects.

Authors:  Yow-Ming C Wang; Wojciech Krzyzanski; Sameer Doshi; Jim J Xiao; Juan Jose Pérez-Ruixo; Andrew T Chow
Journal:  AAPS J       Date:  2010-10-21       Impact factor: 4.009

3.  Numerical validation and properties of a rapid binding approximation of a target-mediated drug disposition pharmacokinetic model.

Authors:  Anshu Marathe; Wojciech Krzyzanski; Donald E Mager
Journal:  J Pharmacokinet Pharmacodyn       Date:  2009-05-12       Impact factor: 2.745

4.  Quasi-equilibrium pharmacokinetic model for drugs exhibiting target-mediated drug disposition.

Authors:  Donald E Mager; Wojciech Krzyzanski
Journal:  Pharm Res       Date:  2005-09-22       Impact factor: 4.200

5.  Pharmacokinetic analysis of continuous erythropoietin receptor activator disposition in adult sheep using a target-mediated, physiologic recirculation model and a tracer interaction methodology.

Authors:  Mohammed H El-Komy; John A Widness; Peter Veng-Pedersen
Journal:  Drug Metab Dispos       Date:  2011-01-05       Impact factor: 3.922

6.  Pharmacokinetics of anti-hepcidin monoclonal antibody Ab 12B9m and hepcidin in cynomolgus monkeys.

Authors:  Jim J Xiao; Wojciech Krzyzanski; Yow-Ming Wang; Hongyan Li; Mark J Rose; Mark Ma; Yuling Wu; Beth Hinkle; Juan Jose Perez-Ruixo
Journal:  AAPS J       Date:  2010-08-25       Impact factor: 4.009

7.  A Novel Combination Therapy of Erythropoietin and Thrombopoietin to Treat Erythropoietin-Resistance anemia.

Authors:  Huixi Zou; Peng Xu; Raymond S M Wong; Xiaoyu Yan
Journal:  Pharm Res       Date:  2022-06-03       Impact factor: 4.200

8.  Pharmacokinetic and pharmacodynamic modeling of romiplostim in animals.

Authors:  Wojciech Krzyzanski; Liviawati Sutjandra; Juan Jose Perez-Ruixo; Bethlyn Sloey; Andrew T Chow; Yow-Ming Wang
Journal:  Pharm Res       Date:  2012-12-19       Impact factor: 4.200

Review 9.  Concept of Pharmacologic Target-Mediated Drug Disposition in Large-Molecule and Small-Molecule Compounds.

Authors:  Guohua An
Journal:  J Clin Pharmacol       Date:  2019-12-02       Impact factor: 3.126

10.  Romiplostim dose-response in patients with myelodysplastic syndromes.

Authors:  Juan Jose Perez Ruixo; Sameer Doshi; Yow-Ming C Wang; Diane R Mould
Journal:  Br J Clin Pharmacol       Date:  2013-06       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.